Ziltivekimab Clinical Trials (2026): 11 Studies for Inflammation & Cardiovascular Risk
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
11 Ziltivekimab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 9 indications (including Inflammation & Cardiovascular Risk) and 23,259 total planned enrollment. 7 Phase 3 Ziltivekimab trials and 2 Phase 2 are listed. 3 Ziltivekimab clinical trials are actively recruiting at 6 U.S. sites across 6 states. Most recent activity: NCT07301034 (Feb 2029).
Where to Participate: All Ziltivekimab Trial Sites in the U.S. (6 sites across 6 states)
Every actively recruiting Ziltivekimabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Winter Haven Hospital | Winter Haven33881 | NCT06118281 | Map |
| MS | Cardiolg Assoc Rsch LLC_Tupelo | Tupelo38801 | NCT06118281 | Map |
| NY | Jacobi Medical Center | The Bronx10461 | NCT06118281 | Map |
| ND | Trinity Medical Group | Minot58701 | NCT06118281 | Map |
| PA | Chambersburg Hospital | Chambersburg17201 | NCT06118281 | Map |
| TX | Methodist Healthcare System of San Antonio | San Antonio78229 | NCT06118281 | Map |
Ziltivekimab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 2 | 2 | ||
| P2 | 2 | 2 | ||
| P3 | 3 | 3 | 1 | 7 |
Recruiting Ziltivekimab clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07301034 | ZEPHYRA Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack | P3 | Myocardial Infarction | 332 | Dec 2025 |
| NCT07276282 | ZEPHYREffects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction | P3 | Coronary Artery Disease | 332 | Dec 2025 |
| NCT06118281 | ARTEMISARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | P3 | Cardiovascular Risk | 10,000 | Jun 2024 |
Ziltivekimab clinical trials by indication
Cardiovascular Risk (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06118281 | ARTEMIS | P3 | recruiting | ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack |
| NCT05021835 | ZEUS | P3 | completed | ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation |
Heart Failure (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05636176 | HERMES | P3 | active not recruiting | A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation |
| NCT06200207 | ATHENA | P3 | active not recruiting | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation |
Coronary Artery Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07276282 | ZEPHYR | P3 | recruiting | Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction |
Myocardial Infarction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07301034 | ZEPHYR | P3 | recruiting | A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack |
Atherosclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06263244 | SPIDER | P3 | active not recruiting | Specifying the Anti-inflammatory Effects of Ziltivekimab |
Healthy Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05721989 | — | P1 | completed | A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab |
Chronic Kidney Disease and Systemic Inflammation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05379829 | — | P1 | completed | A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation |
Chronic Kidney Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04626505 | RESCUE-2 | P2 | completed | Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan. |
Chronic Kidney Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03926117 | RESCUE | P2 | completed | Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition |
Ziltivekimab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ZEPHYR | NCT07301034 | P3 | recruiting | Myocardial Infarction | 332 | — |
| ZEPHYR | NCT07276282 | P3 | recruiting | Coronary Artery Disease | 332 | — |
| HERMES | NCT05636176 | P3 | active not recruiting | Heart Failure | 4,899 | — |
| ATHENA | NCT06200207 | P3 | active not recruiting | Heart Failure | 680 | — |
| ARTEMIS | NCT06118281 | P3 | recruiting | Cardiovascular Risk | 10,000 | — |
| SPIDER | NCT06263244 | P3 | active not recruiting | Atherosclerosis | 40 | — |
| ZEUS | NCT05021835 | P3 | completed | Cardiovascular Risk | 6,385 | PMID 40318255 |
| RESCUE-2 | NCT04626505 | P2 | completed | Chronic Kidney Disease | 36 | PMID 37211246 |
| RESCUE | NCT03926117 | P2 | completed | Chronic Kidney Diseases | 264 | PMID 35212585 |
All Ziltivekimab trials (11)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07301034 | ZEPHYR | A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack | P3 | recruiting | 332 | Novo Nordisk A/S | Dec 2025 |
| NCT07276282 | ZEPHYR | Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction | P3 | recruiting | 332 | ECRI bv | Dec 2025 |
| NCT05636176 | HERMES | A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | P3 | active not recruiting | 4,899 | Novo Nordisk A/S | May 2023 |
| NCT06200207 | ATHENA | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | P3 | active not recruiting | 680 | Novo Nordisk A/S | Apr 2024 |
| NCT06118281 | ARTEMIS | ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | P3 | recruiting | 10,000 | Novo Nordisk A/S | Jun 2024 |
| NCT06263244 | SPIDER | Specifying the Anti-inflammatory Effects of Ziltivekimab | P3 | active not recruiting | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | May 2024 |
| NCT05021835 | ZEUS | ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation | P3 | completed | 6,385 | Novo Nordisk A/S | Aug 2021 |
| NCT05379829 | A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation | P1 | completed | 24 | Novo Nordisk A/S | May 2022 | |
| NCT05721989 | A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab | P1 | completed | 267 | Novo Nordisk A/S | Feb 2023 | |
| NCT04626505 | RESCUE-2 | Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan. | P2 | completed | 36 | Novo Nordisk A/S | Oct 2020 |
| NCT03926117 | RESCUE | Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition | P2 | completed | 264 | Novo Nordisk A/S | Jun 2019 |
Ziltivekimab clinical trials: frequently asked questions
- How many Ziltivekimab clinical trials are there?
- 11 Ziltivekimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 5 are marked completed.
- Are Ziltivekimab clinical trials recruiting in 2026?
- Yes — 3 Ziltivekimab trials are actively recruiting in 2026, with 6 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Ziltivekimab being studied for?
- Ziltivekimab is being studied for Inflammation, Cardiovascular Risk, Heart Failure, Chronic Kidney Disease, Acute Myocardial Infarction (AMI) and 8 more. The trials are grouped by indication on this page.
- What phase is Ziltivekimab in?
- Ziltivekimab clinical trials span 7 Phase 3, 2 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Ziltivekimab clinical trials?
- The lead sponsor across the most Ziltivekimab trials is Novo Nordisk A/S, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ziltivekimabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: